84910

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild‑type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.